Disappointing Phase III results for ArriVent BioPharma’s lead candidate, firmonertinib, in the treatment of non-small cell lung cancer (NSCLC) have triggered a significant market reaction, with the company’s stock experiencing a sharp decline. The failure to meet the primary endpoint in the FURVENT trial casts a shadow over the drug’s future and highlights the intense competition and evolving treatment paradigms within the challenging EGFR exon 20 insertion mutation (Ex20ins) NSCLC landscape.
ArriVent BioPharma’s stock took a substantial hit, dropping by over 46% in the wake of the announcement that its pivotal Phase III FURVENT trial of firmonertinib failed to achieve its primary objective. The trial investigated firmonertinib as a monotherapy for patients with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring specific EGFR exon 20 insertion mutations. This setback comes at a critical juncture, particularly as rival Johnson & Johnson recently reported positive outcomes for its own NSCLC therapy in the same patient population, underscoring the high stakes and rapid advancements in this therapeutic area.
The FURVENT trial (NCT05607550) assessed firmonertinib at two dosages, 240mg and 160mg, against a control arm receiving platinum-based chemotherapy with pemetrexed, the current first-line standard of care (SoC) for this patient group. The primary endpoint, progression-free survival (PFS) as assessed by blinded independent central review (BICR), was not met. Median PFS was reported at 11 months for the 240mg cohort and 8.4 months for the 160mg cohort. In contrast, the control group achieved a median PFS of 9.5 months.
While the primary endpoint was missed, ArriVent did highlight some positive signals in secondary endpoints. These included observed clinical benefit in terms of PFS as assessed by investigators, and a confirmed objective response rate (ORR) by BIC. Furthermore, the company noted a trend towards improvement in overall survival (OS), although this data was not yet mature. The safety profile of firmonertinib in the FURVENT trial was reported as consistent with previous clinical studies, with no new safety concerns emerging.
A Timeline of Disappointment and Shifting Fortunes
The announcement of the FURVENT trial’s outcome sent shockwaves through the market. ArriVent’s stock, which closed at $28.46 on October 5th, plummeted to $12.09 at the market open on October 6th, eventually closing the day at $15.09, marking a day-on-day decline of 46.98%. The Nasdaq-listed company’s market capitalization, previously $744.05 million, experienced a significant reduction.
This disappointing readout follows a period of significant progress and anticipation for firmonertinib. The drug, an oral, brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor, has demonstrated activity against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. ArriVent had previously secured approval for firmonertinib in China for first-line NSCLC in March 2021.
Furthermore, the drug had garnered significant attention in the U.S. market. It received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. It also obtained orphan drug designation for its use in NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. These designations typically signal the FDA’s belief in the drug’s potential to address serious conditions with unmet medical needs.
Beyond the FURVENT trial, firmonertinib is also being evaluated in a second global Phase III study, ALPACCA (NCT07185997), focusing on first-line NSCLC patients with EGFR PACC mutations. The outcome of this trial will be crucial for the drug’s future development and commercial prospects.
Supporting Data and the Challenging Nature of EGFR Exon 20 Insertions
The failure of firmonertinib to meet its primary endpoint in the FURVENT trial underscores the inherent challenges in treating NSCLC patients with EGFR Exon 20 insertion mutations. These mutations, which account for approximately 12% of all EGFR mutations, have historically been notoriously difficult to treat effectively with existing targeted therapies. Traditional EGFR inhibitors, while highly effective against other EGFR mutations like L858R or exon 19 deletions, often exhibit limited efficacy against Exon 20 insertions due to structural differences that hinder drug binding.
The median PFS observed in the firmonertinib cohorts, while showing some benefit over standard chemotherapy, did not reach the threshold required to demonstrate superiority in the primary endpoint. The current standard of care for these patients, platinum-based chemotherapy with pemetrexed, offers a median PFS of around 9.5 months in this trial. This benchmark highlights the high bar that new therapies must clear to offer a meaningful improvement.
Historically, the prognosis for patients with EGFR Exon 20 insertion mutations has been grim. Median overall survival has typically ranged from 16 to 24 months, with a stark five-year survival rate reported at just 8%. This challenging landscape underscores the urgent need for more effective treatment options, making the failure of ArriVent’s candidate particularly impactful.
The Competitive Landscape: A Tale of Two Readouts
ArriVent’s disappointing news arrives in stark contrast to recent positive developments from Johnson & Johnson (J&J). Just weeks prior, J&J announced that its therapy, Rybrevant (amivantamab-vmjw), in combination with chemotherapy, demonstrated the longest median OS in a Phase III trial for the same EGFR Exon 20 insertion mutation NSCLC patient population.
The PAPILLON trial, which underpinned J&J’s announcement, revealed a statistically significant and clinically meaningful 60% improvement in PFS with the Rybrevant plus chemotherapy combination, meeting its primary endpoint. The median PFS in the triplet arm of this trial reached 11.4 months, compared to 6.7 months in the doublet arm (chemotherapy alone). These results have positioned Rybrevant as a leading contender in this difficult-to-treat subset of NSCLC.
The contrasting outcomes from ArriVent and J&J highlight the dynamic and highly competitive nature of the NSCLC therapeutics market. The success of Rybrevant, coupled with the setback for firmonertinib, could significantly reshape the treatment landscape and influence clinical decision-making for oncologists and patients alike.
Official Responses and Future Directions
Dr. Bing Yao, CEO of ArriVent, acknowledged the trial’s outcome with transparency. "While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study," he stated. He expressed gratitude to the patients, investigators, and clinical teams involved and indicated that the company is "evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib."
The company’s statement suggests that while the primary endpoint was missed, the exploration of firmonertinib’s potential may not be entirely concluded. The observed trends in secondary endpoints, particularly the OS data, could warrant further investigation, depending on the strength of the signals and the company’s strategic priorities. However, the significant stock depreciation reflects the market’s current assessment of the drug’s prospects based on the available data.
Implications for the NSCLC Market and Beyond
The failure of firmonertinib in the FURVENT trial has several significant implications. Firstly, it underscores the immense challenge of developing targeted therapies for EGFR Exon 20 insertion mutations. The unique characteristics of these mutations require novel therapeutic approaches, and not all promising candidates will ultimately succeed.
Secondly, it reinforces the competitive advantage held by companies that achieve positive clinical trial results in this space. J&J’s Rybrevant, with its positive Phase III data, is likely to become a dominant force in the first-line treatment of EGFR Exon 20 insertion NSCLC, potentially limiting the market entry for other agents.
Thirdly, this event serves as a stark reminder of the inherent risks associated with biopharmaceutical development. Even drugs with promising preclinical data, regulatory designations, and prior approvals in other regions can falter in pivotal late-stage trials. Investors and stakeholders will likely scrutinize ArriVent’s future strategy and the potential of its remaining pipeline closely.
The broader NSCLC therapeutics market is a significant and growing sector. According to a GlobalData report, the market across seven major regions (US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $24.1 billion in 2022 and is projected to reach $56.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.9%. This robust growth underscores the ongoing need for innovative treatments, even as individual drug candidates face setbacks.
The future trajectory of firmonertinib will depend on ArriVent’s detailed analysis of the FURVENT data and its strategic decisions regarding further development. The company’s ability to navigate this challenging landscape and potentially pivot its strategy will be closely watched by the oncology community and the financial markets. The NSCLC field continues to evolve rapidly, and the success of treatments for specific genetic mutations remains a critical area of focus for both pharmaceutical innovation and patient care.
About the Author
